The same profile of activation of the adaptive immune response was seen in the prostate cancer patients: predominantly, CD4 T-cell responses were seen with CD8+ responses being variable, while no MUC1-reactive antibodies were induced. This evidence concerns the gene CD8A and prostate carcinoma.